Evidence map›Paper›PMID 32800727›Full record

ArticleEuropean urology2021

Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer.

Daniel J Schaid, Shannon K McDonnell, Liesel M FitzGerald, Lissa DeRycke, Zachary Fogarty, Graham G Giles, Robert J MacInnis, Melissa C Southey, Tu Nguyen-Dumont, Geraldine Cancel-Tassin and 29 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in European urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01221168 (ProGene), which is not on this map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01221168 recruitingnot on this map

ProGene: Etude Genetique et Epidemiologique du Cancer de la Prostate Familial

TypeobservationalSponsorCentre de Recherche sur les Pathologies ProstatiquesRan1996 to 2026Enrolled10,000ConditionsProstate Cancer
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Multiple roles and mechanisms of MUC6 in cancer (Review).International journal of molecular medicine · 2025
    Review
  6. Pharmaceuticals (Basel, Switzerland) · 2024
    Article
  7. Article
  8. Article
  9. Review
  10. NCancer science · 2023
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

39 authors at 20 institutions in 7 countries.

Daniel J SchaidDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA. Electronic address: schaid@mayo.edu.
Shannon K McDonnellDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Liesel M FitzGeraldMenzies Institute for Medical Research, University of Tasmania, Hobart, Australia.
Lissa DeRyckeSpecialized Services, National Marrow Donor Program, Minneapolis, MN, USA.
Zachary FogartyDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Graham G GilesCancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia; Centre for Epidemiology and Biostatistics, The University of Melbourne, Parkville, Victoria, Australia; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia.
Robert J MacInnisCancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia; Centre for Epidemiology and Biostatistics, The University of Melbourne, Parkville, Victoria, Australia.
Melissa C SoutheyCancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia; Department of Clinical Pathology, Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia.
Tu Nguyen-DumontPrecision Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia; Department of Clinical Pathology, Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia.
Geraldine Cancel-TassinCeRePP, Tenon Hospital, Paris, France.
Oliver CussenotCeRePP, Tenon Hospital, Paris, France.
Alice S WhittemoreDepartment of Health Research and Policy, Stanford University, Stanford, CA, USA.
Weiva SiehPopulation Health Science and Policy, Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nilah Monnier IoannidisCenter for Computational Biology and Department of Electrical Engineering and Computer Sciences, University of California, Berkeley, CA, USA.
Chih-Lin HsiehDepartment of Urology, University of Southern California, Los Angeles, CA, USA.
Janet L StanfordDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Johanna SchleutkerInstitute of Biomedicine, University of Turku, and Department of Medical Genetics, Genomics, Laboratory Division, Turku University Hospital, Turku, Finland.
Cheryl D CroppDepartment of Pharmaceutical, Social and Administrative Sciences, McWhorter School of Pharmacy, Samford University, Birmingham, AL, USA.
John CarptenDepartment of Translation Genomics, University of Southern California, Los Angeles, CA, USA.
Josef HoegelDepartment of Human Genetics, University of Ulm, Ulm, Germany.
Rosalind EelesDivision of Genetics and Epidemiology, The Institute of Cancer Research, Sutton Surrey, UK.
Zsofia Kote-JaraiDivision of Genetics and Epidemiology, The Institute of Cancer Research, Sutton Surrey, UK.
Michael J AckermanDivision of Heart Rhythm Services, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA; Division of Pediatric Cardiology, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA; Windland Smith Rice Sudden Death Genomics Laboratory, Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
Christopher J KleinDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Diptasri MandalDepartment of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Kathleen A CooneyDepartment of Medicine and Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA.
Joan E Bailey-WilsonComputational and Statistical Genomics Branch, National Human Genome Research Institute, Baltimore, MD, USA.
Brian HelfandDepartment of Surgery, North Shore University Health System/University of Chicago, Evanston, IL, USA.
William J CatalonaDepartment of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Fredrick WiklundDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Shaun RiskaDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Saurabh BahettiDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Melissa C LarsonDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Lisa Cannon AlbrightDepartment of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
Craig TeerlinkDepartment of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
Jianfeng XuNorthshore University Health System, Evanston, IL, USA.
William IsaacsDepartment of Urology, Johns Hopkins Hospital, Baltimore, MD, USA.
Elaine A OstranderCancer Genetics and Comparative Genomic Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
Stephen N ThibodeauDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Mayo Clinic · USThe University of Melbourne · AUInstitute of Cancer Research · GBMayo Clinic in Arizona · USNational Human Genome Research Institute · USNorthShore University HealthSystem · USSorbonne Université · FRUniversity of Southern California · USUniversity of Utah · USDuke University · USFred Hutch Cancer Center · USIcahn School of Medicine at Mount Sinai · USJohns Hopkins Hospital · USKarolinska Institutet · SELouisiana State University Health Sciences Center New Orleans · USNational Marrow Donor Program · USNorthwestern University · USSamford University · USStanford University · USUniversität Ulm · DE

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4M
Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8M
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
Prostate Cancer Susceptibility: The ICPCG StudyU01CA089600 · NCI · MAYO CLINIC ROCHESTER · PI THIBODEAU, STEPHEN NORMAN · 2002 to 2016
$27.3M
Utah Center for Clinical and Translational ScienceUL1TR002538 · NCATS · UNIVERSITY OF UTAH · PI HESS, RACHEL, MAJERSIK, JENNIFER JUHL · 2018 to 2022
$26.0M
Targeting FOXA1-downstream pathways: a novel therapeutic strategy for castration-resistant prostate cancerP50CA180995 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ABDULKADIR, SARKI A., HUSSAIN, MAHA H · 2015 to 2025
$19.9M
GENETIC EPIDEMIOLOGY OF PROSTATE CANCERR01CA080122 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STANFORD, JANET L · 1999 to 2008
$3.8M
NSAIDS and Other Medications in Prostate Cancer EtiologyR01CA092579 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STANFORD, JANET L · 2001 to 2005
$3.2M
GENETIC POLYMORPHISMS AND PROSTATE CANCER RISKR01CA082664 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STANFORD, JANET L · 1999 to 2001
$350k
PROSTATE CANCER IN RELATION TO VASECTOMYR01CA056678 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STANFORD, JANET L · 1993 to 1997
–
NCATS NIH HHS UL1 TR002538NCI NIH HHS P30 CA014236NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA015704NCI NIH HHS P50 CA180995NCI NIH HHS R01 CA056678NCI NIH HHS R01 CA080122NCI NIH HHS R01 CA082664NCI NIH HHS R01 CA092579NCI NIH HHS U01 CA089600
6 · The paper itself

Abstract

backgroundFamily history of prostate cancer (PCa) is a well-known risk factor, and both common and rare genetic variants are associated with the disease.

objectiveTo detect new genetic variants associated with PCa, capitalizing on the role of family history and more aggressive PCa. DESIGN, SETTING, AND

participantsA two-stage design was used. In stage one, whole-exome sequencing was used to identify potential risk alleles among affected men with a strong family history of disease or with more aggressive disease (491 cases and 429 controls). Aggressive disease was based on a sum of scores for Gleason score, node status, metastasis, tumor stage, prostate-specific antigen at diagnosis, systemic recurrence, and time to PCa death. Genes identified in stage one were screened in stage two using a custom-capture design in an independent set of 2917 cases and 1899 controls. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Frequencies of genetic variants (singly or jointly in a gene) were compared between cases and controls. RESULTS AND LIMITATIONS: Eleven genes previously reported to be associated with PCa were detected (ATM, BRCA2, HOXB13, FAM111A, EMSY, HNF1B, KLK3, MSMB, PCAT1, PRSS3, and TERT), as well as an additional 10 novel genes (PABPC1, QK1, FAM114A1, MUC6, MYCBP2, RAPGEF4, RNASEH2B, ULK4, XPO7, and THAP3). Of these 10 novel genes, all but PABPC1 and ULK4 were primarily associated with the risk of aggressive PCa.

conclusionsOur approach demonstrates the advantage of gene sequencing in the search for genetic variants associated with PCa and the benefits of sampling patients with a strong family history of disease or an aggressive form of disease. PATIENT SUMMARY: Multiple genes are associated with prostate cancer (PCa) among men with a strong family history of this disease or among men with an aggressive form of PCa.

Indexed as

Prostatic NeoplasmsExome SequencingGenes, BRCA2Guanine Nucleotide Exchange FactorsHumansMaleNeoplasm GradingProtein Serine-Threonine KinasesTrypsinGuanine Nucleotide Exchange FactorsProtein Serine-Threonine KinasesPRSS3 protein, humanRAPGEF4 protein, humanTrypsinUlk4 protein, humanCustom-capture sequencingFamilial prostate cancerGenetic risk variantsWhole-exome sequencing

Identifiers

PMID32800727
PMCPMC7881048
OpenAlexW3049406555

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.